Accelerating Biopharmaceutical Manufacturing by Focusing on What Matters — A Conversation with Joao Paulo Mattos of Thermo Fisher Scientific

At the most recent edition of the Biomanufacturing World Summit series recorded last November in San Diego we spoke with Joao Paulo Mattos, Thermo Fisher Scientific's Director, Global Process Validation and CMC Lead, about a number of industry trends and issues he is hearing about. In particular, biopharmaceutical manufacturers and technical operations executives want to accelerate their throughput without sacrificing any of their performance metrics when it comes to quality and compliance. He makes the case that post-pandemic expectations to develop and make medicines faster and more accessible than ever before can be realized by optimizing key capabilities to push the “efficient frontier” of biomanufacturing. Industry leaders need to  strike a balance between speed, cost, and flexibility as they leverage learnings from high product mix. Most importantly? Companies need to focus on getting things right from the start, standardization at the correct level, allowing digital tools to do what they do best, build and scale variety into their operations. Give this episode a listen for more!<br/><br/>--<br/><br/>Joao Paulo Mattos is Director of Global Process Validation and CMC Lead at Thermo Fisher Scientific and has responsibility for process validation and CMC strategy for late stage and commercial programs across six drug substance manufacturing and development sites located globally.Joao Paulo has previously held roles in manufacturing sciences, process validation, and technology transfer. Prior to joining Thermo Fisher Joao Paulo worked for Bluebird bio, TESARO, and Bristol-Myers Squibb.He holds a B.S. in Chemical-Biological Engineering from MIT, and a Ph.D in Bioengineering from Rice University.<br/><br/>--<br/><br/>Thermo Fisher Scientific provides end-to-end drug development, clinical trial logistics and commercial manufacturing solutions to customers of all sizes through our Patheon brand. With more than fifty-five locations around the world, the company has extensive capabilities including drug substance and product development, viral vector services, clinical trial services and commercial-scale manufacturing.www.thermofisher.com/patheon